Share on StockTwits

Pacific Biosciences of California (NASDAQ:PACB) Director William W. Ericson purchased 29,435 shares of Pacific Biosciences of California stock on the open market in a transaction dated Wednesday, August 13th. The stock was purchased at an average price of $4.93 per share, with a total value of $145,114.55. The acquisition was disclosed in a filing with the SEC, which is available at this link.

Shares of Pacific Biosciences of California (NASDAQ:PACB) traded up 3.39% on Friday, hitting $5.18. 876,411 shares of the company’s stock traded hands. Pacific Biosciences of California has a 1-year low of $3.32 and a 1-year high of $8.20. The stock’s 50-day moving average is $5.30 and its 200-day moving average is $5.52. The company’s market cap is $365.9 million.

Pacific Biosciences of California (NASDAQ:PACB) last issued its quarterly earnings data on Thursday, July 24th. The company reported ($0.27) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.15) by $0.12. The company had revenue of $11.40 million for the quarter, compared to the consensus estimate of $11.39 million. During the same quarter last year, the company posted ($0.33) earnings per share. Pacific Biosciences of California’s revenue was up 90.0% compared to the same quarter last year. On average, analysts predict that Pacific Biosciences of California will post $-1.07 earnings per share for the current fiscal year.

Pacific Biosciences, Inc develops Deoxyribonucleic Acid (NASDAQ:PACB) sequencing platform.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.